SASajjad Ghanim Al-Badri

Sajjad Ghanim Al-Badri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sajjad Ghanim Al-Badri has a total of 256 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Failed photon beam therapy following endoscopic endonasal resection of a clival chordoma with oculomotor nerve (CN III) compression

    by Abdullah R Sabah, Mohammed S Sabah, Abbas F Abdul Hussein, Ameen Al-Alwany, Ameer D Hameedi, Sajjad G Al-Badri, Saad F Al-Saedi

    Introduction: Clival chordoma is a rare, locally aggressive tumour whose proximity to the brainstem, optic apparatus and internal carotid arteries limits both surgery and radiotherapy. Case description: A 38-year-old woman presented with a left oculomotor nerve palsy from a clival chordoma encasing the internal carotid arteries. She underwent subtotal endoscopic endonasal resection followed by adjuvant photon radiotherapy to 54 Gy in 27 fractions, as particle therapy was unavailable. The dose could not be escalated because the brainstem and optic apparatus were near tolerance, and no clinical target volume was used. After initial regression, the tumour progressed about 20 months later, causing a new right oculomotor nerve palsy, invading the right cavernous sinus and spreading perineurally along the mandibular nerve (V3) through the foramen ovale into the infratemporal fossa. A second endoscopic decompression of the oculomotor nerve achieved only subtotal resection, and MRI 2 months later showed further progression. Discussion: This case shows where and why the tumour recurred. Adjacent critical structures limited the dose to 54 Gy, well below the 74–76 Gy of contemporary series, and progression arose outside the treated volume, compressing the oculomotor nerve and spreading perineurally along V3, a rarely reported route that target volumes should cover. Learning points:

  • Open Access

    Epidemiological trends and sex disparities in stroke disability-adjusted life years and mortality in Middle East and North Africa (MENA)

    by Ibrahim Khalil, Mohamed Wagdy, Ghassan Adnan Hashim, Hasan Naeem Kareem, Asma Alshanqiti, Md. Imran Hossain, Nabila Nur, Mst. Mahmuda Akter, Amal Abdi Ali, Sajjad Ghanim Al-Badri, et al.

    Stroke remains a leading cause of disability and mortality globally, with pronounced burdens in the Middle East and North Africa (MENA) due to demographic shifts, conflict, and varying healthcare access. This study analyzes temporal trends and sex disparities in stroke-related disability-adjusted life years (DALYs) and deaths across MENA from 1990 to 2023, using Global Burden of Disease 2023 data, and extends projections to 2050 using Seasonal Autoregressive Integrated Moving Average (SARIMA) modeling. Age-standardized rates of stroke DALYs and deaths were extracted for the MENA region and 21 constituent countries, stratified by sex (International Classification of Diseases, 10th Revision: I60–I69). Temporal trends were assessed via estimated annual percentage changes using linear regression on log-transformed rates, with 95% confidence intervals (CIs). SARIMA models were fitted to regional time-series (both sexes) to forecast age-standardized rates through 2050, with 95% prediction intervals constrained to nonnegative values. Regionally, stroke DALYs declined with an estimated annual percentage change of –2.595 (95% CI:–2.641 to –2.549), steeper in females (–2.697; 95% CI:–2.758 to –2.636) than males (–2.487; 95% CI:–2.537 to –2.438). Deaths declined by –2.51 (95% CI:–2.556 to –2.464) overall. Qatar showed the fastest DALY decline (–4.437; 95% CI:–4.859 to –4.014), Libya the slowest (–1.087; 95% CI:–1.205 to –0.97). SARIMA forecasts project a 78.8% reduction in DALYs (from 1895 to 401 per 100,000) and 83.6% in mortality (94 to 15 per 100,000) by 2050, with lower 95% CIs reaching zero by 2043 due to long-term uncertainty. Declining stroke burdens in MENA reflect progress in risk factor control and acute care, with females showing steeper gains in most countries. Forecasts indicate near-elimination of stroke mortality and substantial disability reduction by mid-century, yet persistent sex and country disparities underscore the need for equitable, sustained interventions in prevention, acute management, and rehabilitation across vulnerable MENA settings.

  • Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study

    by Ibrahim Khalil, Pallab Sarker, Nabila Nur, Md. Imran Hossain, Aizaz Anwar Khalid, Sajjad Ghanim Al-Badri, Mst. Mahmuda Akter, Manisha Das, Mohd Turzo Rahman

    Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition with significant cardiometabolic and hepatic risks. Tirzepatide, a dual GLP-1/GIP receptor agonist, shows promise in MASLD, but real-world comparative data against sodium-glucose cotransporter-2 inhibitors (SGLT2is) are lacking. Methods In this multicenter, retrospective, propensity score-matched cohort study using the TriNetX US Collaborative Network, we compared outcomes in 43,743 new tirzepatide initiators versus 43,743 matched SGLT2i users with MASLD and ≥ 1 metabolic comorbidity. Propensity Score Matching (1:1, caliper 0.1) balanced > 50 covariates. Primary outcomes included all-cause mortality, hospitalization, major adverse cardiovascular events (MACE), major adverse liver outcomes (MALO), and major adverse kidney events (MAKE) at 1- and 3-year follow-up, analyzed via Kaplan–Meier estimation and Cox proportional hazards models. Results Tirzepatide was associated with significantly lower risks versus SGLT2is. At 1-year follow-up (n = 43,743 per group), all-cause mortality events were 144 (cumulative incidence 0.48%, KM event-free survival 99.52%) with tirzepatide versus 533 (1.38%, 98.62%) with SGLT2i (HR 0.328, 95% CI 0.272–0.394; log-rank p < 0.0001). All-cause hospitalization occurred in 3033 versus 7143 (HR 0.460, 95% CI 0.441–0.480). MACE events were 1064 versus 2376 (HR 0.506, 95%CI 0.471–0.544). MALO events were 149 versus 465 (HR 0.379, 95% CI 0.315–0.456). Hepatic failure and ascites also favored tirzepatide, while MAKE, varices, and hepatic encephalopathy showed no significant differences. Benefits persisted at 3 years (n = 39,838 per group): mortality 208 versus 963 (HR 0.374, 95% CI 0.321–0.436); hospitalization 3723 versus 9548 (HR 0.528, 95%CI 0.508–0.549); MACE 1260 versus 3282 (HR 0.545, 95%CI 0.510–0.582); and MALO 220 versus 726 (HR 0.478, 95%CI 0.410–0.558). Conclusions In this large real-world MASLD cohort, tirzepatide was associated with substantial reductions in mortality, hospitalizations, cardiovascular, and liver-related events compared to SGLT2is. These observational findings suggest potential advantages of tirzepatide and warrant prospective validation in randomized trials. Graphical abstract

  • Open Access

    Co-occurrence of Griscelli Syndrome Type 2 and Systemic Juvenile Idiopathic Arthritis in a Pediatric Patient: A Case Report

    by Ali Falah Zbala, Haneen Sedqi Al Fhrnawie, Diyar Sedqi Al Fhrnawie, Sajjad Ghanim Al-Badri, Ibrahim Khalil

    Griscelli syndrome type 2 (GS2) is a rare autosomal recessive immunodeficiency disorder characterized by silver-colored hair, fair skin, and an increased risk of developing hemophagocytic lymphohistiocytosis (HLH). Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory condition distinguished by daily fevers, transient rash, and arthritis, with macrophage activation syndrome being a known complication. We present a case involving an 18-month-old female with persistent fever, rash, and joint inflammation. Laboratory findings revealed elevated inflammatory markers and hyperferritinemia, prompting concern for HLH, though full diagnostic criteria were not satisfied. A unique clinical sign led to extended evaluation, and genetic testing confirmed the presence of GS2. Concurrent clinical features also met the requirements for sJIA. To the best of our knowledge, this is the first reported instance of GS2 co-occurring with sJIA. This case highlights a potential shared susceptibility to immune dysregulation and raises the possibility that immunodeficiency may reveal or influence the manifestation of autoinflammatory diseases. Prompt recognition is essential in managing atypical and treatment-resistant inflammatory presentations.

  • Open Access

    Global trends, sex- and country-specific disparities in nonalcoholic fatty liver disease (NAFLD) mortality: A comprehensive analysis of the Global Burden of Disease data across 204 countries (1990–2023)

    by Ibrahim Khalil, Sajjad Ghanim Al-Badri, Md. Imran Hossain, Athar Ud Din, Mahfuja Jahan Ima, Mohd Turzo Rahman, Mst. Mahmuda Akter, Lota Halder, Arindam Das Joy, Sunjida Amin Promi, et al.

    Nonalcoholic fatty liver disease (now termed metabolic dysfunction-associated steatotic liver disease [MASLD]) is a leading cause of liver-related mortality worldwide, linked to the rising prevalence of metabolic syndrome. Despite prior analyses using earlier Global Burden of Disease (GBD) iterations, comprehensive trends incorporating post-2020 data remain limited. This study provides the first analysis utilizing the latest GBD 2023 release, examining global, sex-, and country-specific disparities in MASLD age-standardized mortality rates (ASMR) from 1990 to 2023 across 204 countries, highlighting the impact of recent events like the COVID-19 pandemic on metabolic health. MASLD ASMR data were extracted from the GBD 2023 database, defined by International Classification of Diseases, 10th Revision codes. Estimated annual percentage changes (EAPC) in ASMR were calculated using logarithmic linear regression. Analyses were stratified by sex and country, with 95% confidence intervals derived from the standard error of β. Globally, the mean EAPC was 0.152% (range: −3.079% in the Republic of Korea to 4.143% in Kazakhstan) for both sexes, 0.020% for females (−3.630% in Bermuda to 4.612% in the Russian Federation), and 0.291% for males (−2.970% in the Republic of Korea to 4.277% in Turkmenistan). Increases predominated in 111 countries (54.4%), with significance in 94; declines in 93, significant in 78. Pronounced rises occurred in Eastern Europe/Central Asia (e.g., Kazakhstan, Russian Federation) and the Middle East (e.g., Oman), while declines were evident in East Asia (e.g., the Republic of Korea) and Southern Europe (e.g., Italy). Males showed higher EAPC in 119 countries, with a mean sex difference of 0.271%; notable disparities included Cuba (males 3.296% vs females −0.172%). Country-specific trends revealed vulnerabilities in low- and middle-income countries, with mixed patterns in Africa. This inaugural GBD 2023 analysis reveals a modest global rise in MASLD mortality, with regional surges in transitioning economies and male-predominant disparities. Urgent, tailored interventions targeting metabolic risks are essential to mitigate this escalating burden.

  • Open Access

    Efficacy of Mavacamten on functional capacity in hypertrophic cardiomyopathy: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials

    by Ibrahim Khalil, Anannya Sheikh, Nabila Nur, Imran Hossain, Mahmuda Akter, Sajjad Ghanim Al-Badri

    Background: Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, often leading to left ventricular outflow tract (LVOT) obstruction, heart failure, and sudden cardiac death. Mavacamten, a novel cardiac myosin inhibitor, targets the underlying mechanisms of HCM. Methods: We searched PubMed, Cochrane Library, and ClinicalTrials.gov up to 1 August 2025 and included six randomized controlled trials comparing Mavacamten to placebo in adults with HCM. The primary outcome was the change in LVOT gradients (post-exercise, post-Valsalva, and resting). Secondary outcomes included N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, left ventricular ejection fraction, peak oxygen consumption (pVO 2 ), and serious adverse events (SAEs). Data were analyzed using a random-effects model, with results reported as mean differences (MD) or risk ratios (RR) with 95% confidence intervals (CI). Meta-regression explored study-level moderators, and retrospective trial sequential analysis assessed the robustness of the findings. Results: Among 632 patients, Mavacamten significantly reduced LVOT gradients: post-exercise (MD: −38.28 mmHg, 95% CI: −45.92 to −30.63, P < 0.00001), post-Valsalva (MD: −59.02 mmHg, 95% CI: −82.75 to −35.29, P < 0.00001), and resting (MD: −44.50 mmHg, 95% CI: −66.49 to −22.51, P < 0.0001). NT-proBNP levels decreased significantly (MD: −617.26 ng/L, 95% CI: −772.43 to −462.09, P < 0.00001), but pVO 2 showed no significant change (MD: 0.69 mL/kg/min, 95% CI: −1.12 to 2.50, P = 0.45). SAEs were comparable (RR: 1.17, 95% CI: 0.58–2.36, P = 0.66). Across primary outcomes, retrospective trial sequential analysis confirms that Mavacamten’s reductions in LVOT gradients are conclusive, indicating robust evidence. Conclusion: Mavacamten effectively reduces LVOT gradients and NT-proBNP levels in HCM, but its impact on exercise capacity remains uncertain, with no increased risk of SAEs.

  • Open Access

    Effectiveness of vericiguat in heart failure across ejection fraction phenotypes: a comprehensive meta-analytic trial sequential analysis and meta-regression analysis

    by Ibrahim Khalil, M. Rafiqul Islam, Manisha Das, Sunjida Amin Promi, Sajjad Ghanim Al-Badri, Sakib Abrar, Afsana Rahman Maliha, Avijit Debnath, Md Ekramul Islam, Akm Mushfiquzzaman, et al.

    Background: Heart failure (HF) remains a global health challenge, with distinct phenotypes – heart failure with reduced ejection fraction (HFrEF ≤40%) and heart failure with preserved ejection fraction (HFpEF ≥50%) – requiring tailored therapies. Vericiguat, a soluble guanylate cyclase stimulator, targets the nitric oxide -soluble guanylate cyclase-cyclic guanosine monophosphate pathway to reduce cardiac stress, showing promise in HFrEF but with unclear efficacy in HFpEF. This meta-analysis evaluates Vericiguat’s effectiveness across HF phenotypes using trial sequential analysis (TSA) and meta-regression. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we included eight randomized controlled trials (17,381 patients) comparing Vericiguat to control in HFrEF and HFpEF patients. Outcomes assessed were hospitalization for HF, all-cause mortality, cardiovascular mortality, and the composite endpoint (cardiovascular death or first hospitalization). Random-effects models calculated pooled risk ratio (RR). TSA controlled for type I/II errors, and meta-regression explored covariates (age, sex, NT-proBNP, HF subgroup). Sensitivity analyses assessed robustness. Results: Vericiguat reduced hospitalization for HF (RR: 0.90, 95% confidence interval [CI]: 0.82–0.98, P = 0.0201) and the composite endpoint (RR: 0.88, 95% CI: 0.78–0.99, P = 0.035), but TSA indicated inconclusive evidence (required information sizes: 29,929 and 48,016 patients, respectively). No significant effect was observed for all-cause mortality (RR: 0.98, 95% CI: 0.68–1.40, P = 0.904) or cardiovascular mortality (RR: 0.91, 95% CI: 0.64–1.30, P = 0.6091). Heterogeneity was minimal ( I 2 = 0–17%). Meta-regression showed no significant covariate effects, though HFrEF trended toward benefit ( P = 0.1329). Sensitivity analysis identified VITALITY-HFpEF as an influential outlier. Conclusions: Vericiguat modestly reduces hospitalization and composite outcomes in HF, particularly HFrEF, but lacks mortality benefits. Larger, phenotype-specific trials are needed to confirm efficacy, especially in HFpEF, to refine Vericiguat’s role in HF management.

  • Open Access

    Comparative effectiveness of cholesteryl ester transfer protein (CETP) inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis and network meta-regression

    by Ibrahim Mbbs Khalil, M Rafiqul Mbbs Islam, Sunjida Amin Mbbs Promi, Arindam Das Joy, Abu Sayed, Durjoy Mbbs Acharjee, Ali Saad MBChB Al-Shammari, Mohd Turzo Rahman, Sakib Mbbs Abrar, Ta-Seen Mbbs Bin Jamil, et al.

    Background: Cardiovascular disease remains the leading cause of mortality worldwide, with residual cardiovascular (CVS) risk remaining high despite pharmacological interventions. Cholesteryl ester transfer protein (CETP) inhibitors have shown promise in improving lipid profiles, but their comparative effectiveness in reducing CVS outcomes remains unclear. This network meta-analysis and network meta-regression aimed to evaluate the comparative effectiveness of CETP inhibitors (Evacetrapib, Anacetrapib, Dalcetrapib, and Torcetrapib) on CVS outcomes, including CVS mortality, all-cause mortality, major adverse cardiovascular events, myocardial infarction, need for revascularization, and stroke. Methods: A Bayesian network meta-analysis was conducted, incorporating data from 10 randomized controlled trials with 84,134 patients diagnosed with cardiovascular disease or at high risk. We compared various CETP inhibitors for their effectiveness in reducing CVS events. Network meta-regression was used to assess the impact of covariates such as age, sex, and baseline lipid levels. Results: Evacetrapib ranked highest for CVS mortality (relative risk [RR]: 0.92, 95% credible interval [CrI]: 0.39–1.87; Surface Under the Cumulative Ranking Curve [SUCRA]: 71.91%) and Anacetrapib for major adverse cardiovascular events (RR: 0.40, 95% CrI: 0.07–1.06; SUCRA: 84.25%). Dalcetrapib showed favorable effects on all-cause mortality (RR: 0.72, 95% CrI: 0.16–1.42; SUCRA: 67.51%) and stroke (RR: 0.75, 95% CrI: 0.41–1.26; SUCRA: 83.03%). Anacetrapib had the highest rank in reducing myocardial infarction (RR: 0.83, 95% CrI: 0.46–1.15; SUCRA: 86.06%). Conclusions: This analysis suggests that Evacetrapib and Anacetrapib are the most effective CETP inhibitors for improving CVS outcomes, with Dalcetrapib showing beneficial effects in certain outcomes. Further studies are needed to confirm these findings.

  • Open Access

    Comparative efficacy of ceftolozane–tazobactam versus ceftazidime–avibactam for Pseudomonas aeruginosa infections: a GRADE-assessed systematic review and meta-analysis

    by Asim Shah, Syeda Vilay Zehra Rizvi, Javeria Nawaz, Hammad Saif, Syeda Umme Abiha Rizvi, Diya Rathi, Sabika Fatima, Suleman Khan, Aizaz Anwar Khalid, Sajjad Ghanim Al Badri, et al.

    Background: Infections caused by multidrug-resistant/difficult-to-treat (MDR/DTR) Pseudomonas aeruginosa present a significant challenge for treatment. Ceftolozane–tazobactam (C/T) and ceftazidime–avibactam (C/A) are important options that combine β-lactam and β-lactamase inhibitors, but their effectiveness compared to each other is still unclear. Methods: We performed a systematic review and meta-analysis, evaluated by Grading of Recommendations Assessment, Development, and Evaluation (GRADE), of comparative observational studies that included hospitalized adults with confirmed MDR/DTR P. aeruginosa infections up to 10 October 2025 (English only). Studies comparing C/T directly with C/A and matched therapies were included. We used random-effects Mantel–Haenszel models to calculate pooled risk ratios (RR) with 95% confidence intervals (CIs), and we assessed heterogeneity with I 2 . We reviewed the certainty of evidence using GRADE. Results: Six observational cohorts ( n = 1161) met our criteria. There were no significant differences between C/T and C/A for clinical success (RR: 1.07, 0.89–1.29; I 2 = 40%), 30-day all-cause mortality (RR: 1.02, 95% CI: 0.83–1.27; I 2 = 0%), 30-day recurrence (RR: 0.85, 0.46–1.57; I 2 = 48%), 90-day recurrence (RR: 0.80, 0.63–1.02; I 2 = 0%; P = 0.08), emergence of resistance (RR: 0.73, 0.30–1.81; I 2 = 84%), and microbiological response failure (RR: 0.91, 0.66–1.26; I 2 = 8%). There was a non-significant trend that slightly favored C/T for 90-day recurrence. According to GRADE, the certainty of evidence varied from low to very low, mainly due to non-randomized study designs and variability across studies. Conclusions: In current comparative cohorts, C/T and C/A show similar outcomes for severe MDR/DTR P. aeruginosa infections. More high-quality randomized trials are needed to better define any potential differences and clarify long-term recurrence and resistance risks.


  • Comparative Effectiveness of High‐Dose and Standard‐Dose Influenza Vaccines for Hospitalisation and Mortality in Adults Aged 65 and Older: An Updated Systematic Review and Meta‐Analysis

    by Bilal Wazir Khan, Muhammad Huzaifa Khattak, Muhammad Maaz Amjad, Shahreena Athar Siddiqui, Tayyaba Ikram Qazi, Hamdullah Rehmat, Muhammad Faaz Khan, Haris Wazir Khan, Affan Masaud Mian, Mohsin Ullah, et al.

    This updated systematic review and meta‐analysis evaluated the relative vaccine effectiveness (rVE) of high‐dose inactivated influenza vaccine (HD‐IV) versus standard‐dose (SD‐IV) in adults ≥ 65 years for key clinical outcomes, including hospitalisations and mortality. Conducted in accordance with PRISMA guidelines, PubMed, Embase, and the Cochrane Library were searched for randomised controlled trials. Primary outcomes were pneumonia and influenza (P&I) hospitalisation, all‐cause hospitalisation, and all‐cause mortality, while secondary outcomes included hospitalisation for cardiorespiratory disease, influenza‐related hospitalisation, laboratory‐confirmed influenza hospitalisation, and serious adverse events (SAEs). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using fixed‐effect models. Across 586,188 participants, HD‐IV reduced P&I hospitalisation (rVE 12.0%), increasing to 22.0% in sensitivity analysis. For all‐cause hospitalisation (∼600,000 participants), rVE was 4.0%, while no significant reduction was observed for all‐cause mortality (rVE = 2.0%). Subgroup analyses suggested greater benefits in individuals without cardiovascular disease and those aged 65–79 years. HD‐IV also showed strong protection against influenza‐specific outcomes (rVE 39% for influenza hospitalisation; 32% for laboratory‐confirmed influenza hospitalisation), with no significant difference in SAEs between groups. Overall, HD‐IV provides superior protection compared with SD‐IV against P&I and all‐cause hospitalisation in older adults, with the greatest benefits among younger seniors and those without cardiovascular disease. These findings support prioritising HD‐IV to reduce influenza burden in the elderly, although benefits appear limited in adults aged > 80 years.